CD19 and B-cell non-Hodgkin lymphoma: A phase I/II clinical trial (NCT03056339) aims to test efficacy and safety of CB-NK redirected with CAR.CD19-CD28-zeta-2A-iCasp9-IL-15 in patients with B-cell lymphoma treated with a high dose of chemotherapy and stem cell transplantation.